Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP5 | P51878 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309097 | 0.94 | ADRB1 (0.54) | ADRB1KDM4EALDH1A1HRH3ROCK2 | |
| SCHEMBL4947574 | 0.83 | KDM1A (0.48) | ADRB1KDM4EALDH1A1ACHEKDM1A | |
| SCHEMBL10187275 | 0.83 | KDM1A (0.48) | ADRB1ROCK2ACHEKDM1AOGA | |
| SCHEMBL9900073 | 0.81 | KDM1A (0.47) | KDM4EALDH1A1ROCK2ACHEKDM1A | |
| SCHEMBL11113633 | 0.80 | ADRB1 (0.61) | ADRB1KDM4EALDH1A1HRH3ROCK2 | |
| SCHEMBL15740788 | 0.79 | AOC3 (0.42) | ADRB1KDM4EHRH3ROCK2KDM1A | |
| SCHEMBL27738163 | 0.79 | ACHE (0.51) | ADRB1KDM4EALDH1A1ROCK2ACHE | |
| SCHEMBL5797268 | 0.79 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1HRH3ROCK2 | |
| SCHEMBL5758330 | 0.79 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1HRH3ROCK2 | |
| SCHEMBL573580 | 0.79 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1HRH3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101363779-B | Method for enhancing ionization efficiency of peptide segment | UNIV FUDAN | 2011-07-27 | — | — | CN | claimed |
| CN-101363779-A | Method for enhancing ionization efficiency of peptide segment | UNIV FUDAN (CN) | 2009-02-11 | — | — | CN | claimed |
| JP-58057370-A | — | — | None | — | — | JP | disclosed |
| JP-62096474-A | — | — | None | — | — | JP | disclosed |
| CN-111587112-B | Rho-related inhibitors of coiled-coil-containing protein kinases | 卡德门企业有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| US-20130274475-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274475-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-17 | — | — | US | disclosed |
| US-8487093-B2 | β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487093-B2 | β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| CN-102603570-A | Preparation method for 2,3,4-trimethoxy benzonitrile | UNIV HENAN SCIENCE & TECH | 2012-07-25 | — | — | CN | disclosed |
| EP-0039190-A1 | 2-(1-Piperazinyl)-4-pyrimidinamines and related compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-11-04 | — | — | EP | disclosed |
| EP-0039190-A1 | 2-(1-Piperazinyl)-4-pyrimidinamines and related compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-11-04 | — | — | EP | disclosed |
| WO-1981003022-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PROD (US) | 1981-10-29 | — | — | WO | disclosed |
| WO-1981003022-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PROD (US) | 1981-10-29 | — | — | WO | disclosed |
| WO-1981003022-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PROD (US) | 1981-10-29 | — | — | WO | disclosed |
| EP-0056027-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-10-29 | — | — | EP | disclosed |
| EP-0056027-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-10-29 | — | — | EP | disclosed |
| EP-0056027-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-10-29 | — | — | EP | disclosed |
| US-3962443-A | Antibacterial pharmaceutical compositions and processes for preparation thereof | DAINIPPON PHARMACEUTICAL CO., LTD. (JA) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274475-A1 | BETA-LACTAMASE INHIBITORS | MGAM, RPIA, XDH | ADRB1 313/4885KDM4E 2600/4885ALDH1A1 422/4885 |
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | ADRB1 3462/4885KDM4E 893/4885ALDH1A1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.